AIDS最新文献

{"title":"A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks.","authors":"Zachary R Stephen, Simone Perazzolo, Luqi Duan, Masa Eguchi, Baoping Tian, Keegan Klein, Loren Kinman, Rachele Delle Fratte, Kristina M Adams Waldorf, Theresa Barton, Ann J Melvin, Rodney J Y Ho","doi":"10.1097/QAD.0000000000004531","DOIUrl":"10.1097/QAD.0000000000004531","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the novel 3-in-one long-acting injectable product composed of tenofovir alafenamide (TAF), dolutegravir (D), and lamivudine (L), as a complete TAF-DL product for pediatric HIV treatment.</p><p><strong>Design: </strong>TAF-DL sterile injectable product is assembled with three HIV drugs and amphipathic lipids. It is built on the drug-combination-nanoparticle (DcNP) platform via a well defined manufacturing process. Plasma concentrations for all three drugs were determined in 12 juvenile non-human primates (NHP, Macaca nemestrina ) following subcutaneous administration. Safety parameters monitored.</p><p><strong>Results: </strong>Following a single dose of TAF-DL-in-DcNP , all drugs exhibited long-acting cell-and-plasma profiles in juvenile NHP for 8  weeks. Time-to-peak occurred within 24 h for all drugs. Compared to free-soluble counterpart, DcNP formulation enhanced the half-life of TAF, D, and L by 23-fold, 5.8-fold, 8.3-fold, respectively, and area under the curve (AUC) by 41-fold, 18-fold, 3.1-fold. Cell targeting enabled by DcNP is noted as higher intracellular PBMC versus plasma concentration of TAF, tenofovir (T), D, L in NHP dosed with TAF-DL-in-DcNP product. Safety assessment in 12 juvenile NHPs noted no injection-site reactions, or change in weight, complete blood count, and serum chemistries over 8  weeks.</p><p><strong>Conclusion: </strong>Current 3-HIV oral drugs, TAF-DL is successfully transformed into a novel, single long-acting injectable product that may support once every 2 month dosing. TAF-DL-in-DcNP enhanced HIV host-lymphocyte drug exposure. With less than 24  h to reach Cmax , the all-in-one product may overcome the need for an oral lead-in typically required to initiate LA injectables. TAF-DL-in-DcNP product appears to be safe in juvenile NHPs.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1420-1425"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13584648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort.","authors":"Jimmy Ma, Stephanie A Ruderman, Lara Haidar, Joseph A Delaney, H Nina Kim, Diana Alba, Kristina Crothers, Sherif Eltonsy, Sonya Heath, Y Joseph Hwang, Maile Karris, Kenneth H Mayer, Sonia Napravnik, April C Pettit, Allan Rodriguez, Bridget M Whitney, George Yendewa, Michael S Saag, Mari M Kitahata, Heidi M Crane","doi":"10.1097/QAD.0000000000004544","DOIUrl":"10.1097/QAD.0000000000004544","url":null,"abstract":"<p><strong>Objectives: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis are key drivers of morbidity and mortality in people with HIV (PWH). Limited evidence exists in PWH for managing MASLD and liver fibrosis with semaglutide.</p><p><strong>Methods: </strong>We studied adult PWH in care at 10 CFAR Network of Integrated Clinical Systems sites who initiated semaglutide for diabetes and/or weight loss and had liver fibrosis score (FIB-4) data from 4/2018-11/2024. We used adjusted linear mixed models for a quasi-experimental, pre-/post-, new-user analysis of semaglutide on FIB-4 score with several a priori stratifications by baseline fibrosis category and other relevant clinical factors.</p><p><strong>Results: </strong>Among 1850 PWH at baseline, 1368 had FIB-4 <1.3 (no/low fibrosis), 428 had FIB-4 1.3-2.67 (moderate fibrosis), and 54 had FIB-4 >2.67 (advanced fibrosis). Most PWH had cardiometabolic conditions (diabetes 59%, dyslipidemia 62%, hypertension 80%, BMI ≥30 80%), drank alcohol with low levels of use (57%, mean AUDIT-C 1.6), and did not have hepatitis B (93%) or hepatitis C infection (86%). Mean time on semaglutide was 218 days. Semaglutide was associated with reductions in liver fibrosis score in PWH with baseline moderate-to-advanced fibrosis (FIB-4 ≥1.3; ΔFIB-4: -0.11, P < 0.01) with greatest decreases in advanced fibrosis (FIB-4 >2.67; ΔFIB-4: -0.64, P < 0.001).</p><p><strong>Conclusions: </strong>Semaglutide was associated with declines in liver fibrosis scores in PWH with moderate-to-advanced fibrosis and high levels of cardiometabolic conditions. Together with evidence from the general population, these findings suggest that semaglutide could help manage MASLD and liver fibrosis in PWH, especially as PWH age and experience long-term impacts of cardiometabolic disease.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1474-1479"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147947448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors associated with adverse metabolic health in youth with perinatally acquired HIV living in the United Kingdom.","authors":"Caroline Foster, Alexandra Blenkinsop, Merle Henderson, Hermione Lyall, Sarah Fidler","doi":"10.1097/QAD.0000000000004533","DOIUrl":"10.1097/QAD.0000000000004533","url":null,"abstract":"<p><strong>Objective: </strong>Non-AIDS-related morbidity and mortality in people with HIV are associated with adverse metabolic health, influenced by both traditional-related and HIV-related risk factors. There is a paucity of data for youth with perinatal HIV (PHIV). We explored the relationship between markers of metabolic health and antiretroviral therapy (ART) in youth with PHIV.</p><p><strong>Design: </strong>Longitudinal observational cohort study; 26 months.</p><p><strong>Methods: </strong>Eighty-five youth enrolled in the 'Bone Density in Youth living with PHIV' (BONDY) underwent assessment of metabolic health including fasting biochemistry, BMI, total body dual energy x-ray absorptiometry scan and hepatic transient elastography.</p><p><strong>Results: </strong>Of 85 participants with PHIV, mean age 21.7 years, 58% were female and 82% black African. Median ART exposure was 15 years, median CD4 + cell count 623 cells/μl at enrolment with 82% viral load less than 200 copies/ml. Median weight gain over 26 months was 3 kg, with BMI category overweight/obese increasing from 37 to 50% with 48% having dyslipidaemia. Metabolic syndrome criteria were fulfilled in 7%, with 13% having hypertension, 18% hepatic steatosis, and 7% fibrosis on transient elastography. Bayesian regression analyses demonstrated no association of integrase strand transfer inhibitor (INSTI) and/or tenofovir alafenamide (TAF) use, and sex at birth or prior CDC-C diagnoses or current HIV viraemia on metabolic outcomes.</p><p><strong>Conclusion: </strong>While adverse metabolic outcomes are common in this youth cohort with PHIV, no association was observed with INSTI and/or TAF use. Given the relatively young age of this cohort, preventative interventions targeting traditional metabolic risk factors are required to avoid comorbidities in later life.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1459-1466"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13566416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Same-day initiation of tenofovir alafenamide-based pre-exposure prophylaxis with drug-level feedback for transgender women in Uganda.","authors":"Andrew Mujugira, Rogers Nsubuga, Agnes Nakyanzi, Monica Bagaya, Olivia Nampewo, Oliver Sapiri, Felix Bambia, Timothy R Muwonge, Monica Gandhi, Jessica E Haberer","doi":"10.1097/QAD.0000000000004542","DOIUrl":"10.1097/QAD.0000000000004542","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the feasibility and acceptability of same-day initiation of emtricitabine/tenofovir alafenamide (F/TAF) pre-exposure prophylaxis (PrEP) and test the impact of drug-level feedback on PrEP adherence among transgender women (TGW) in Uganda.</p><p><strong>Design: </strong>Randomized controlled trial.</p><p><strong>Methods: </strong>HIV-negative TGW were randomly assigned 1 : 1 to intervention (drug-level feedback with tailored adherence counseling) or standard-of-care (SOC), and followed quarterly for 12 months (November 2021-July 2023; NCT04491422). Quarterly clinic visits included demographic and socio-behavioral data collection, PrEP refills, STI testing, and quarterly PrEP adherence assessment using tenofovir levels in dried blood spots (DBS; long-term) and urine (short-term).</p><p><strong>Results: </strong>We enrolled 200 TGW (100 per arm), median age 21 years. Same-day F/TAF PrEP initiation was 100%. Tenofovir detection in urine (intervention arm) was 79, 80, 85, and 70% at the 3, 6, 9, and 12-month visits, respectively. Tenofovir detection in DBS was 46, 40, 35, and 31% at 3, 6, 9, and 12 months, respectively. Median tenofovir DBS concentrations were 40.6 and 47.0 fmol/punch in intervention and SOC arms, respectively. There was no intervention effect on PrEP adherence (DBS tenofovir levels) [adjusted incidence rate ratio (aIRR) 1.06; 95% CI: 0.82-1.37]. Never being harassed by police for being transgender (aIRR 1.66; 95% CI: 1.24-2.23), history of taking daily medication for more than 7 days (aIRR 1.51; 95% CI: 1.18-1.93) and higher monthly income (aIRR 1.44; 95% CI: 1.10-2.04) were associated with PrEP adherence.</p><p><strong>Conclusion: </strong>Oral F/TAF PrEP adherence among TGW in Uganda was low and not affected by drug-level feedback or tailored adherence counseling. Long-acting injectable PrEP formulations should be considered for this population.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 10","pages":"1508-1516"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148823918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent or recurrent cervical dysplasia in women with HIV after treatment for high-grade dysplasia in Botswana.","authors":"Devon A Harris, Rafaela Germano Toledo, Michele Hacker, Bridgette Wamakima, Leatile Sedabadi, Kelebogile Gaborone, Lorato Mochoba, Lapelo Ntshese, Surbhi Grover, Roger Shapiro, Matthys H Botha, Katharine M Esselen, Doreen Ramogola-Masire, Rebecca Luckett","doi":"10.1097/QAD.0000000000004551","DOIUrl":"10.1097/QAD.0000000000004551","url":null,"abstract":"<p><strong>Objective: </strong>To determine histopathologic outcomes 1 year after loop electrosurgical excision procedure (LEEP) for CIN2/CIN3 in women living with HIV on antiretroviral therapy (ART) in Botswana and assess whether a 12-month follow-up interval is appropriate.</p><p><strong>Methods: </strong>This was a prospective cohort study of women with HIV who previously underwent LEEP for confirmed CIN2/CIN3. Participants underwent follow-up approximately 12  months later, either through Ministry of Health or a standardized sub-study protocol, with colposcopy or visual inspection with acetic acid (VIA) and tissue sampling performed per clinical algorithm. The primary outcome was histopathologically confirmed CIN2+ at follow-up. Associations between clinical factors, demographics, and CIN2+ were evaluated; chi-square and two-sample T -test were used to compare data and risk ratios were calculated.</p><p><strong>Results: </strong>Of 127 eligible participants, 90 attended follow-up at a median of 16 months (IQR 13-20). Almost all were on ART with a mean CD4 + cell count of 728 (SD ± 310) cells/μl. Of 66 participants with histopathology results, 29% had CIN2+ and one participant had invasive cancer. Positive endocervical margins at baseline were associated with increased risk of CIN2+, while age, time on ART, and CD4 + cell count were not. Follow-up interval of at least 24  months was associated with more than double the risk of CIN2+ at follow-up (crude risk ratio 2.3, 95% confidence interval 1.1-4.7).</p><p><strong>Conclusion: </strong>In a cohort of women with HIV on ART, 29% had persistent/recurrent CIN2+ at follow-up. Follow-up interval and endocervical margin status were the strongest predictors. These data support the WHO recommendation for a 12-month follow-up interval in women living with HIV who are well controlled on ART.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1426-1434"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The additive value of coronary calcium in identifying cardiovascular risk in ageing people with HIV.","authors":"Maithili Varadarajan, Ruth Byrne, Abethale Al-Hussaini, Brian Halliday, Edward Nicol, Mark Nelson, Alan Winston, Marta Boffito","doi":"10.1097/QAD.0000000000004514","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004514","url":null,"abstract":"<p><p>In people without HIV, raised coronary artery calcium scores (CACS) are linked to increased cardiovascular risk. HIV is associated with elevated CACS, but risk factors beyond smoking and diabetes are not well established. Data on 779 individuals with HIV who underwent a CACS scans (median age 55) were collected. CACS better predicted adverse outcomes (e.g. major adverse cardiovascular events (MACE), death, heart failure) than Q-risk scores. Advanced imaging research may improve major cardiovascular risk prediction in people ageing with HIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 10","pages":"1582-1585"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148823892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylation patterns linked to blood pressure in people with HIV exposed to antiretroviral therapy reveal neurovascular and immune pathways.","authors":"Samson Okello, Mariaelisa Graff, Anne E Justice, Annie Green Howard, Beth D Jamieson, Roger Shih, Heather McKay, Sadeep Shrestha, Jacquelyn Meyers, Eun-Young Kim, Seble Kassaye, Yasmeen Golzar, David B Hanna, Madhu Chhanda Choudhary, Anna A Rubtsova, Margaret A Fischl, Katherine C Wu, Kesava Asam, Catalina Ramirez, Bradley E Aouizerat, Andrew Edmonds, Kari E North","doi":"10.1097/QAD.0000000000004569","DOIUrl":"10.1097/QAD.0000000000004569","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a leading contributor to cardiovascular disease in people with HIV (PWH), yet its underlying molecular mechanisms remain poorly understood.</p><p><strong>Methods: </strong>We conducted a cross-sectional methylome-wide association study (MWAS) of blood pressure (BP) and arterial hypertension in 1131 PWH (739 women, 392 men; mean age 43 years) in the MACS/WIHS Combined Study (MWCCS), to identify differentially methylated positions (DMPs) and regions (DMRs) associated with SBP, DBP, and hypertension.</p><p><strong>Results: </strong>We identified 59 DMPs associated with SBP and 60 associated with DBP [false discovery rate (FDR) P  < 0.05], enriched in vascular, metabolic, and immune pathways. Top DMPs near ATP8B2 gene [3.8% DNA methylation (DNAm) per SD change in SBP], MIR378E gene (- 9.5% DNAm per SD change in SBP), SNORA114 gene (5.2% DNAm per SD change in DBP), and ANXA11 gene (- 7.9% DNAm per SD change in DBP). A total of 204 DMPs were associated with hypertension, including a top hypermethylated DMP near GSE1 gene [odds ratio = 0.014, 95% confidence interval (CI) 0.013-0.015, P  = 1.32e -16 ] per 1% increase in DNAm. Gene enrichment analysis showed associations with BP-relevant tissues including kidney, brain, vasculature, and adipose tissue. We found 23 DMRs associated with DBP, including a 19-DMP region in CTBP1 gene, and 136 DMRs associated with hypertension, the largest spanning BAZ2A and LMNTD1 genes.</p><p><strong>Conclusion: </strong>We identified HIV/antiretroviral therapy (ART)-specific and shared epigenetic loci associated with BP traits, implicating neurovascular, renometabolic, and immune-regulatory pathways in HIV/ART-related hypertension.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1407-1419"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148429645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-dependent mortality effects of dynamic antiretroviral therapy regimens.","authors":"Yali Niu, Ning Li, Xuezhong Shi, Xiaocan Jia, Chenyu Zhao, Nana Wang, Yongli Yang","doi":"10.1097/QAD.0000000000004546","DOIUrl":"10.1097/QAD.0000000000004546","url":null,"abstract":"<p><strong>Introduction: </strong>To compare the mortality effects of dynamic antiretroviral therapy (ART) regimens among people with HIV (PWH), while accounting for time-varying CD 4+ T cell counts and HIV viral loads.</p><p><strong>Methods: </strong>Leveraging data from 32 713 ART-naïve individuals (2015-2024) in Henan, China, we compared three approaches: baseline, time-fixed Cox model that classified participants by ART class at initiation, time-varying Cox model that updated ART class over follow-up; and marginal structural model (MSM) to address time-varying confounding. ART regimens were classified as nonnucleoside reverse transcriptase inhibitor (NNRTI)-, integrase strand transfer inhibitor (INSTI)-, or protease inhibitor (PI)-based regimens (reference: NNRTI). Outcomes included all-cause mortality and AIDS-related mortality.</p><p><strong>Results: </strong>Effect estimates shifted from the baseline time-fixed model toward stronger protective associations after incorporating time-updated ART exposure and further adjusting for time-varying confounding. In the MSM, compared with NNRTI-based regimens, INSTI- and PI-based regimens were associated with lower all-cause mortality [INSTI: hazard ratio (HR) = 0.38, 95% confidence interval (CI): 0.29-0.49; PI: HR=0.69, 95% CI: 0.52-0.91] and lower AIDS-related mortality (INSTI: HR = 0.31, 95% CI: 0.17-0.57; PI: HR = 0.47, 95% CI: 0.25-0.89). Secondary exploratory cumulative exposure analyses yielded patterns broadly consistent with lower mortality for INSTI exposure, whereas estimates for PI exposure were closer to the null and should be interpreted cautiously.</p><p><strong>Conclusion: </strong>Accounting for time-updated ART exposure and time-varying confounding, INSTI-based regimens were associated with lower all-cause and AIDS-related mortality than NNRTI-based regimens. These findings underscore the need to account for dynamic ART exposure and time-varying confounding in observational comparative effectiveness studies of ART regimens.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1530-1538"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147969623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver disease risk attributable to HCV, HIV, and HCV-HIV coinfection: an interaction analysis.","authors":"William J McFarlane, Jennifer A Flemming, Jorge L Martinez-Cajas, Yingwei Peng, Susan B Brogly","doi":"10.1097/QAD.0000000000004555","DOIUrl":"10.1097/QAD.0000000000004555","url":null,"abstract":"<p><strong>Objective: </strong>To quantify whether living with HIV modifies the effect of hepatitis C (HCV) infection on risk of cirrhosis, hepatic decompensation (decompensation), and hepatocellular carcinoma (HCC) in a real-world healthcare context.</p><p><strong>Design: </strong>A cohort of 1 484 587 individuals from Ontario, Canada that tested negative for HCV antibodies (HCV Ab-) were followed from 1999 to 2018 for diagnoses of HCV, HIV, cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma, using administrative health data.</p><p><strong>Methods: </strong>Time-dependent Cox regression was used to quantify the risk of each liver disease outcome in individuals who were positive for HCV and HIV (HCV+/HIV+), only HCV+ (HCV+/HIV-), only HIV+ (HCV-/HIV+), and doubly negative (HCV-/HIV-). The relative excess risk due to interaction (RERI) was calculated to quantify the magnitude and significance of interaction effects.</p><p><strong>Results: </strong>HCV+/HIV+ had the highest risk of cirrhosis [hazard ratio (HR) = 3.8; 95% confidence interval (CI): 2.9, 4.9], decompensation (HR = 2.8; 95% CI: 1.9, 4.1), and HCC (HR = 4.1; 95% CI: 2.7, 6.2) compared to HCV-/HIV-. A significant positive interaction effect was observed for risk of decompensation (RERI = 1.2; 95% CI: 0.1, 2.3) and HCC (RERI = 2.3; 95% CI: 0.6, 4.0), but not for risk of cirrhosis (RERI = 0.9; 95% CI: -0.1, 2.0).</p><p><strong>Conclusions: </strong>This large population-based cohort study is the first to estimate the interaction effect of HCV and HIV on liver disease risk, providing new evidence of a synergistic additive interaction effect between HCV and HIV infection on risk of decompensation and HCC.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1552-1560"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.","authors":"Cinthia S Lamaizón, Diego Cecchini, Martin Brizuela, Gastón Copertari, Brenda Bacelar, Macarena Roel, Edgardo Bottaro, Lidia I Cassetti","doi":"10.1097/QAD.0000000000004553","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004553","url":null,"abstract":"<p><p>Resistance-associated mutations (RAMs) limit treatment options for HIV. We evaluated virologic outcomes in people with HIV harboring RAMs who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a real-world cohort during 4 years of follow-up. Virologic suppression was sustained across RAM subgroups, including M184V/I with additional nucleoside reverse transcriptase inhibitor (NRTI)-RAMs. Stratification by genotypic susceptibility score (GSS) suggests robust effectiveness. B/F/TAF demonstrates durable long-term suppression in different resistance profiles, supporting its use in this population.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 10","pages":"1587-1590"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148823939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}